Results 121 to 130 of about 14,439 (224)

Switching From Originator to Biosimilar Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis

open access: yesJCC Plus, Volume 1, Issue 6, November 2026.
In this meta‐analysis of eight studies (508 children with inflammatory bowel disease), switching from originator to biosimilar infliximab preserved clinical remission, drug exposure, and immunogenicity, with high treatment persistence and no signal of efficacy or safety loss. Biosimilar switching appears a safe, effective option in pediatric IBD.
Douglas Amaral da Silva Menegazzo Miotto   +4 more
wiley   +1 more source

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

open access: yesJPGN Reports, Volume 7, Issue 4, Page 536-543, November 2026.
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah   +9 more
wiley   +1 more source

Biosimilars [PDF]

open access: yesProceedings of the National Academy of Sciences, 2015
G.-R. Burmester, U. Müller-Ladner
openaire   +4 more sources

EMERGING BIOSIMILARS IN ONCOLOGY: A REVIEW [PDF]

open access: yes, 2018
Biosimilars are the biological medicinal products that produce the therapeutic effects in the human body similar to that of inner biological molecule.
B, Lavanya
core   +1 more source

Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics /

open access: yes
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products.
Herzyk, Danuta J.,editor.   +1 more
core  

Biosimilars 2024

open access: yes
Biosimilars, a rapidly growing category of medications in The United States of America (US), play a vital role in addressing health conditions. This study provides a comprehensive overview of the distinctions between Biosimilars and Generics, examining ...
AMOL MANDHARE (18275845)
core   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

open access: yesInternational Journal of Dermatology, Volume 65, Issue 11, Page 2362-2370, November 2026.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco   +13 more
wiley   +1 more source

The advent of biosimilars: challenges and risks

open access: yes, 2014
Biosimilars represent a new class of medicinal products that will have significant impact on clinical use. They are identical on an amino acid sequence level to existing reference biopharmaceutical products (originals).
Rüdiger Müller   +11 more
core   +1 more source

Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia

open access: yesФармакоэкономика
Background. The increasing number of registered biosimilars of monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers.
A. Yu. Efremov   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy